Patient data capture software company uMotif has raised £5m in a Series A investment round led by existing investor AlbionVC.

The desktop and smartphone-based software is designed to collect data from patients in virtual trials in a user-friendly way, and store the resulting data.

Its tech is used in studies taking place in 26 countries from clinical to real-world settings, and across more than 25 therapeutic areas – from dermatology and rare disease to oncology and cardiology.

The funding, which also saw participation from Oslo-based DNV-GL and existing angel investors, will fuel further development of its patient-centric and decentralised approach to clinical studies.

The funding will also be used to enable expansion into new study types and more high-demand territories outside of its core customer base in Europe and the US.

“We’re excited to help our customers implement patient-centred research designs by using the uMotif platform to capture high-quality data,” said Bruce Hellman, CEO and Co-Founder of uMotif.

“This new funding will rapidly accelerate our development and will ultimately help our customers to get new therapies to patients faster”.

Dr. Andrew Elder, Deputy Managing Partner at investor AlbionVC added: “Now more than ever, having access to reliable patient data during clinical trials is crucial. uMotif’s platform is built with patients in mind; designed to help academics, researchers and healthcare professionals to capture the best quality data in a way that suits the participants.”